-DOCSTART- -X- O
OBJECTIVES -X- _ O
: -X- _ O
We -X- _ O
aimed -X- _ O
to -X- _ O
describe -X- _ O
patterns -X- _ O
in -X- _ O
the -X- _ O
usage -X- _ O
of -X- _ O
antivirals -X- _ B-Intervention
to -X- _ O
treat -X- _ O
influenza -X- _ B-Patient
virus -X- _ I-Patient
infection -X- _ I-Patient
in -X- _ O
hospitals -X- _ O
in -X- _ O
Hong -X- _ O
Kong -X- _ O
from -X- _ O
2000 -X- _ O
through -X- _ O
2015. -X- _ O
METHODS -X- _ O
: -X- _ O
We -X- _ O
analyzed -X- _ O
centralized -X- _ O
electronic -X- _ O
health -X- _ O
records -X- _ O
that -X- _ O
included -X- _ O
dispensation -X- _ O
information -X- _ O
and -X- _ O
diagnosis -X- _ O
codes. -X- _ O
Information -X- _ O
collected -X- _ O
on -X- _ O
admissions -X- _ O
included -X- _ O
patient -X- _ O
age -X- _ O
, -X- _ O
sex -X- _ O
, -X- _ O
admission -X- _ O
year -X- _ O
and -X- _ O
month -X- _ O
, -X- _ O
and -X- _ O
medications -X- _ O
dispensed -X- _ O
, -X- _ O
and -X- _ O
were -X- _ O
matched -X- _ O
with -X- _ O
the -X- _ O
first -X- _ O
15 -X- _ O
discharge -X- _ O
diagnosis -X- _ O
codes. -X- _ O
We -X- _ O
divided -X- _ O
monthly -X- _ O
admission -X- _ O
episodes -X- _ O
by -X- _ O
relevant -X- _ O
population -X- _ O
denominators -X- _ O
to -X- _ O
obtain -X- _ O
admission -X- _ O
rates -X- _ O
, -X- _ O
and -X- _ O
stratified -X- _ O
analyses -X- _ O
by -X- _ O
drug -X- _ O
type -X- _ O
, -X- _ O
age -X- _ O
group -X- _ O
, -X- _ O
and -X- _ O
diagnosis -X- _ O
codes. -X- _ O
RESULTS -X- _ O
: -X- _ O
Amantadine -X- _ B-Outcome
was -X- _ I-Outcome
used -X- _ I-Outcome
for -X- _ I-Outcome
influenza -X- _ I-Outcome
treatment -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
early -X- _ I-Outcome
2000s -X- _ I-Outcome
but -X- _ I-Outcome
changed -X- _ I-Outcome
with -X- _ I-Outcome
recommendations -X- _ I-Outcome
to -X- _ I-Outcome
avoid -X- _ I-Outcome
its -X- _ I-Outcome
use -X- _ I-Outcome
in -X- _ I-Outcome
2006 -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
is -X- _ I-Outcome
now -X- _ I-Outcome
mainly -X- _ I-Outcome
used -X- _ I-Outcome
to -X- _ I-Outcome
treat -X- _ I-Outcome
Parkinson’s -X- _ I-Outcome
disease. -X- _ I-Outcome
Oseltamivir -X- _ I-Outcome
usage -X- _ I-Outcome
increased -X- _ I-Outcome
substantially -X- _ I-Outcome
in -X- _ I-Outcome
2009 -X- _ I-Outcome
and -X- _ I-Outcome
is -X- _ I-Outcome
now -X- _ I-Outcome
commonly -X- _ I-Outcome
used -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
almost -X- _ I-Outcome
40,000 -X- _ I-Outcome
hospitalizations -X- _ I-Outcome
treated -X- _ I-Outcome
with -X- _ I-Outcome
oseltamivir -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
years -X- _ I-Outcome
2012 -X- _ I-Outcome
through -X- _ I-Outcome
2015 -X- _ I-Outcome
, -X- _ I-Outcome
66 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
which -X- _ I-Outcome
was -X- _ I-Outcome
in -X- _ I-Outcome
persons -X- _ I-Outcome
≥65 -X- _ I-Outcome
years -X- _ I-Outcome
of -X- _ I-Outcome
age. -X- _ I-Outcome
During -X- _ I-Outcome
the -X- _ I-Outcome
entire -X- _ I-Outcome
study -X- _ I-Outcome
period -X- _ I-Outcome
, -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
98,253 -X- _ I-Outcome
admission -X- _ I-Outcome
episodes -X- _ I-Outcome
in -X- _ I-Outcome
which -X- _ I-Outcome
oseltamivir -X- _ I-Outcome
was -X- _ I-Outcome
dispensed -X- _ I-Outcome
, -X- _ I-Outcome
40,698 -X- _ I-Outcome
( -X- _ I-Outcome
41 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
included -X- _ I-Outcome
a -X- _ I-Outcome
diagnosis -X- _ I-Outcome
code -X- _ I-Outcome
for -X- _ I-Outcome
influenza -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
80,283 -X- _ I-Outcome
( -X- _ I-Outcome
82 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
included -X- _ I-Outcome
any -X- _ I-Outcome
diagnosis -X- _ I-Outcome
code -X- _ I-Outcome
for -X- _ I-Outcome
respiratory -X- _ I-Outcome
illness. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
The -X- _ B-Outcome
amount -X- _ I-Outcome
of -X- _ I-Outcome
oseltamivir -X- _ I-Outcome
used -X- _ I-Outcome
from -X- _ I-Outcome
2012–15 -X- _ I-Outcome
was -X- _ I-Outcome
comparable -X- _ I-Outcome
to -X- _ I-Outcome
a -X- _ I-Outcome
separate -X- _ I-Outcome
ecological -X- _ I-Outcome
estimate -X- _ I-Outcome
of -X- _ I-Outcome
around -X- _ I-Outcome
13,000 -X- _ I-Outcome
influenza- -X- _ I-Outcome
associated -X- _ I-Outcome
hospitalizations -X- _ I-Outcome
per -X- _ I-Outcome
year -X- _ I-Outcome
on -X- _ I-Outcome
average. -X- _ I-Outcome
We -X- _ O
did -X- _ O
not -X- _ O
have -X- _ O
access -X- _ O
to -X- _ O
individual -X- _ O
patient -X- _ O
laboratory -X- _ O
testing -X- _ O
data -X- _ O
. -X- _ O

